全文获取类型
收费全文 | 1364篇 |
免费 | 68篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 75篇 |
妇产科学 | 17篇 |
基础医学 | 178篇 |
口腔科学 | 71篇 |
临床医学 | 105篇 |
内科学 | 256篇 |
皮肤病学 | 7篇 |
神经病学 | 44篇 |
特种医学 | 137篇 |
外科学 | 182篇 |
综合类 | 43篇 |
一般理论 | 2篇 |
预防医学 | 55篇 |
眼科学 | 78篇 |
药学 | 96篇 |
1篇 | |
中国医学 | 6篇 |
肿瘤学 | 75篇 |
出版年
2023年 | 10篇 |
2022年 | 22篇 |
2021年 | 81篇 |
2020年 | 56篇 |
2019年 | 53篇 |
2018年 | 59篇 |
2017年 | 44篇 |
2016年 | 49篇 |
2015年 | 52篇 |
2014年 | 50篇 |
2013年 | 103篇 |
2012年 | 114篇 |
2011年 | 88篇 |
2010年 | 64篇 |
2009年 | 36篇 |
2008年 | 58篇 |
2007年 | 54篇 |
2006年 | 65篇 |
2005年 | 47篇 |
2004年 | 49篇 |
2003年 | 32篇 |
2002年 | 14篇 |
2001年 | 3篇 |
2000年 | 3篇 |
1999年 | 5篇 |
1998年 | 23篇 |
1997年 | 24篇 |
1996年 | 18篇 |
1995年 | 19篇 |
1994年 | 15篇 |
1993年 | 10篇 |
1991年 | 5篇 |
1990年 | 10篇 |
1989年 | 13篇 |
1988年 | 5篇 |
1987年 | 4篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 7篇 |
1982年 | 4篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 6篇 |
1975年 | 4篇 |
1961年 | 3篇 |
1958年 | 2篇 |
1954年 | 2篇 |
1953年 | 2篇 |
排序方式: 共有1441条查询结果,搜索用时 984 毫秒
21.
22.
23.
24.
25.
Neha?Singh Avinash?C.?Tripathi Aseem?Tewari Ravi?Kumar Shailendra?K.?SarafEmail author 《Medicinal chemistry research》2015,24(5):1927-1941
A series of new 5-aryliden-2-imino-4-thiazolidinones (5a–e and 6a–e) were synthesized via a three-step reaction and characterized by physicochemical and spectral data. The uniqueness of the derivatives lies in the fact that none of them had an acidic group, like conventional NSAIDS, but exhibited significant in vivo activity in acute inflammation models. In particular, 5-(3-chlorobenzyliden)-2-(pyridin-2-yl-imino)-4-thiazolidinone(5a) and 5-(3-chlorobenzyliden)-2-(5-methylisoxazol-3-yl-imino)-4-thiazolidinone (6a) showed remarkable paw oedema inhibition (67.76 and 74.47 % oedema inhibition, respectively, after 3 h) comparable to that of Ibuprofen (74.56 % oedema inhibition, after 3 h) at half of the dose of the standard drug. Also, compounds 5a (72.86 %) and 6a (80.20 %) were found to possess significant inhibition of albumin denaturation when screened for in vitro anti-inflammatory activity. In addition, these compounds were docked into the known active site of COX-2 protein using Glide XP and QPLD algorithms, and the binding-free energy was calculated using Prime MM/GBSA simulation methods. The combined use of molecular docking and MM/GBSA methods gave a good correlation between the predicted binding-free energy and experimentally determined biological activities. It was also evident from the docking results that 2-methylisoxazolylimino or 2-(pyridin-2-yl-imino substitution and 3-chloro moiety on 5-benzylidin nucleus of these 4-thiazolidinone derivatives can easily occupy the COX-2 binding pocket, considered as the critical interaction for COX-2 inhibition. Moreover, pharmacokinetic properties of all the synthesized compounds were predicted, with good results. Further, the synthesized derivatives showed neither acute toxicity nor symptoms of gastric ulceration, at extended doses, owing to the absence of an acidic group. 相似文献
26.
Janis E. Blair Ashwini Gotimukul Fangfang Wang Syeda A. Mina Helen C. Bartels Mark W. Burns Amy E. Kole Holenarasipur R. Vikram Juan C. Gea-Banacloche M. Teresa Seville Skye A. Buckner Petty Avinash Vikram Robert Orenstein 《Medicine》2021,100(24)
Most patients with coronavirus disease 2019 (COVID-19) have mild to moderate illness not requiring hospitalization. However, no study has detailed the evolution of symptoms in the first month of illness.At our institution, we conducted remote (telephone and video) visits for all adult outpatients diagnosed with COVID-19 within 24 h of a positive nasopharyngeal polymerase chain test for SARS-CoV-2. We repeated regular video visits at 7, 14, and 28 days after the positive test, retrospectively reviewed the prospective data collected in the remote visits, and constructed a week by week profile of clinical illness, through week 4 of illness.We reviewed the courses of 458 symptomatic patients diagnosed between March 12, 2020, and June 22, 2020, and characterized their weekly courses. Common initial symptoms included fever, headache, cough, and chest pain, which frequently persisted through week 3 or longer. Upper respiratory or gastrointestinal symptoms were much shorter lived, present primarily in week 1. Anosmia/ageusia peaked in weeks 2 to 3. Emergency department visits were frequent, with 128 visits in the 423 patients who were not hospitalized and 48 visits among the 35 outpatients (7.6%) who were eventually hospitalized (2 subsequently died). By the fourth week, 28.9% said their illness had completely resolved. After the 4-week follow up, 20 (4.7%) of the 423 nonhospitalized patients had further medical evaluation and management for subacute or chronic COVID-19 symptoms.Mild to moderate outpatient COVID-19 is a prolonged illness, with evolving symptoms commonly lasting into the fourth week of illness. 相似文献
27.
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy 总被引:2,自引:1,他引:2
Brown RA; Herzig RH; Wolff SN; Frei-Lahr D; Pineiro L; Bolwell BJ; Lowder JN; Harden EA; Hande KR; Herzig GP 《Blood》1990,76(3):473-479
Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs that can be combined without bone marrow transplantation. Etoposide was administered over 29 to 69 hours by continuous infusion corresponding to total doses of 1.8 g/m2 to 4.8 g/m2. Cyclophosphamide, 50 mg/kg/d, was administered on 3 or 4 consecutive days total 150 to 200 mg/kg ideal body weight). At all dose levels myelosuppression was severe but reversible. Mucosal toxicity was dose-limiting with the maximum tolerated dose level combining etoposide 4.2 g/m2 with cyclophosphamide 200 mg/kg. Continuous etoposide infusion produced stable plasma levels that were lower than would be achieved after administration by short intravenous infusion, and this could explain our ability to escalate etoposide above the previously reported maximum tolerated dose. There were 28 complete (35%) and 12 partial (16%) responses. Median duration of complete response (CR) was 3.5 months (range 1.1 to 20+). Seventeen of 40 patients (42%) with acute myelogenous leukemia (AML) achieved CR, including 6 of 20 (30%) with high-dose cytosine arabinoside resistance. We conclude that bone marrow transplantation is not required after maximum tolerated doses of etoposide and cyclophosphamide. This regimen is active in resistant hematologic neoplasms, and the occurrence of CR in patients with high-dose cytosine arabinoside-resistant AML indicates a lack of complete cross-resistance between these regimens. 相似文献
28.
Kazimierz O. Wrzeszczynski Vanessa Felice Avinash Abhyankar Lukasz Kozon Heather Geiger Dina Manaa Ferrah London Dino Robinson Xiaolan Fang David Lin Michelle F. Lamendola-Essel Depinder Khaira Esra Dikoglu Anne-Katrin Emde Nicolas Robine Minita Shah Kanika Arora Olca Basturk Vaidehi Jobanputra 《The Journal of molecular diagnostics : JMD》2018,20(6):822-835
29.
Jay Kumar Chhablani Riddhima Deshpande Virender Sachdeva Sagar Vidya P Srinivasa Rao Anand Panigati Birendra Mahat Rajeev Reddy Pappuru Niranjan Pehere Avinash Pathengay 《Indian journal of ophthalmology》2015,63(6):474-477